Open Payments

Butler Hospital

Type
Teaching hospital
Where
Providence, RI
Medicare CCN
414000
Received
$2,679,595 in 86 records, 2023 ($0 general, $2,679,595 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2023Research payment86$2,679,595

By company

CompanyRecordsAmountYears
Eisai Inc.52$1,477,9122023
Biogen, Inc.2$381,0902023
Eli Lilly and Company3$374,2262023
Janssen Research & Development, LLC20$333,5502023
GE HEALTHCARE1$53,3902023
Genentech, Inc.7$49,4252023
Neuronetics, Inc.1$10,0002023

By nature of payment

NatureRecordsAmount
Research payment86$2,679,595

Records

DateCompanyAmountNatureFormProductStudyYear
2023-12-27Janssen Research & Development, LLC$52,896Research paymentCash or cash equivalentA Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ62023
2023-12-21Genentech, Inc.$32,671Research paymentCash or cash equivalentPhase II study for Moderate AD2023
2023-12-14Eisai Inc.$46,387Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2023
2023-12-01Eisai Inc.$21,080Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-12-01Eisai Inc.$10,955Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-12-01Eisai Inc.$8,335Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-11-22Eisai Inc.$35,604Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2023
2023-11-02Neuronetics, Inc.$10,000Research paymentCash or cash equivalentNeurostar TMS Therapy System Device, Neurostar TMS Therapy SystemEMA-Guided Adaptive- Schedule TMS Maintenance Therapy2023
2023-11-01Genentech, Inc.$1,485Research paymentCash or cash equivalentPhase II study for Moderate AD2023
2023-10-23Janssen Research & Development, LLC$1,533Research paymentCash or cash equivalentA Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ62023
2023-10-19Eisai Inc.$231,294Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2023
2023-10-19Eisai Inc.$33,567Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2023
2023-10-06Janssen Research & Development, LLC$8,512Research paymentCash or cash equivalentA Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ62023
2023-10-01Eisai Inc.$21,560Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-10-01Eisai Inc.$20,580Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-10-01Eisai Inc.$15,660Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-10-01Eisai Inc.$11,955Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-10-01Eisai Inc.$9,705Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-10-01Eisai Inc.$7,710Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-09-21Eisai Inc.$61,906Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2023
2023-09-11Janssen Research & Development, LLC$26,226Research paymentCash or cash equivalentA Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ62023
2023-09-01Eisai Inc.$26,660Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-09-01Eisai Inc.$9,300Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-09-01Eisai Inc.$5,330Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-09-01Janssen Research & Development, LLC$5,099Research paymentCash or cash equivalentSPRAVATO Drug, NeuroscienceA Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression2023
2023-08-29Eli Lilly and Company$270,581Research paymentCash or cash equivalentA STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6)2023
2023-08-18Eisai Inc.$1,864Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2023
2023-08-10Janssen Research & Development, LLC$47,647Research paymentCash or cash equivalentA Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ62023
2023-07-24Eisai Inc.$73,641Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2023
2023-07-10Janssen Research & Development, LLC$22,163Research paymentCash or cash equivalentA Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ62023
2023-07-07Janssen Research & Development, LLC$2,438Research paymentCash or cash equivalentSPRAVATO Drug, NeuroscienceA Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression2023
2023-07-03Janssen Research & Development, LLC$8,837Research paymentCash or cash equivalentSPRAVATO Drug, NeuroscienceA Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression2023
2023-07-01Eisai Inc.$77,125Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-07-01Eisai Inc.$26,590Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-07-01Eisai Inc.$22,770Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-06-09Janssen Research & Development, LLC$21,055Research paymentCash or cash equivalentA Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ62023
2023-06-01Eli Lilly and Company$103,155Research paymentCash or cash equivalentANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY2023
2023-06-01Janssen Research & Development, LLC$8,597Research paymentCash or cash equivalentSPRAVATO Drug, NeuroscienceA Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression2023
2023-05-19Eisai Inc.$67,756Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2023
2023-05-11Janssen Research & Development, LLC$24,527Research paymentCash or cash equivalentA Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ62023
2023-05-08Eisai Inc.$26,458Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2023
2023-05-04Janssen Research & Development, LLC$500Research paymentCash or cash equivalentA Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ62023
2023-05-01Eisai Inc.$24,880Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-05-01Janssen Research & Development, LLC$8,885Research paymentCash or cash equivalentSPRAVATO Drug, NeuroscienceA Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression2023
2023-05-01Eisai Inc.$8,540Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-05-01Eisai Inc.$4,670Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-04-27GE HEALTHCARE$53,390Research paymentIn-kind items and servicesVizamyl Drug, CORE IMAGINGFLUTE-21-01B: BioFINDER-Brown: Examination of Alzheimer's Disease Biomarkers (TRACE-B)2023
2023-04-20Eisai Inc.$1,222Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2023
2023-04-20Genentech, Inc.$119Research paymentCash or cash equivalentPhase II study for Moderate AD2023
2023-04-20Genentech, Inc.$119Research paymentCash or cash equivalentPhase II study for Moderate AD2023
2023-04-13Eli Lilly and Company$490Research paymentIn-kind items and servicesA STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6)2023
2023-04-10Janssen Research & Development, LLC$14,577Research paymentCash or cash equivalentA Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ62023
2023-04-05Eisai Inc.$61,393Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2023
2023-04-01Eisai Inc.$26,635Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-04-01Eisai Inc.$14,120Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-04-01Eisai Inc.$13,760Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-04-01Eisai Inc.$9,135Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-04-01Eisai Inc.$5,760Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-04-01Eisai Inc.$5,320Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-03-24Janssen Research & Development, LLC$3,882Research paymentCash or cash equivalentSPRAVATO Drug, NeuroscienceA Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression2023
2023-03-14Genentech, Inc.$6,773Research paymentCash or cash equivalentPhase II study for Moderate AD2023
2023-03-01Eisai Inc.$13,310Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-03-01Eisai Inc.$2,600Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-03-01Eisai Inc.$290Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-02-27Janssen Research & Development, LLC$6,649Research paymentCash or cash equivalentSPRAVATO Drug, NeuroscienceA Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression2023
2023-02-20Eisai Inc.$57,479Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2023
2023-02-20Janssen Research & Development, LLC$3,331Research paymentCash or cash equivalentA Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ62023
2023-02-03Janssen Research & Development, LLC$57,177Research paymentCash or cash equivalentA Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ62023
2023-02-01Eisai Inc.$52,835Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-02-01Eisai Inc.$31,015Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-02-01Eisai Inc.$30,795Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-02-01Eisai Inc.$24,760Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-02-01Eisai Inc.$19,505Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-02-01Eisai Inc.$17,160Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-02-01Eisai Inc.$13,780Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-02-01Eisai Inc.$10,445Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-02-01Eisai Inc.$7,500Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-02-01Eisai Inc.$5,160Research paymentCash or cash equivalentLeqembi Drug, NeurologyAHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to 2023
2023-01-30Janssen Research & Development, LLC$9,014Research paymentCash or cash equivalentSPRAVATO Drug, NeuroscienceA Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression2023
2023-01-20Biogen, Inc.$358,221Research paymentCash or cash equivalentADUHELM Biological, NeurologyPhase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previ2023
2023-01-20Eisai Inc.$38,562Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2023
2023-01-18Genentech, Inc.$6,773Research paymentCash or cash equivalentPhase II study for Moderate AD2023
2023-01-18Genentech, Inc.$1,485Research paymentCash or cash equivalentPhase II study for Moderate AD2023
2023-01-12Biogen, Inc.$22,869Research paymentCash or cash equivalentADUHELM Biological, NeurologyPhase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previ2023
2023-01-06Eisai Inc.$103,266Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2023
2023-01-06Eisai Inc.$216Research paymentCash or cash equivalentLeqembi Drug, NeurologyA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2023

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Providence CountyProvidence city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Providence, RI, county Providence County, RI, state Rhode Island; placed by its city name.

MeasurePlace (city or town)
Providence, RI
County
Providence County, RI
State
Rhode Island
Population B01003191,767664,8541,101,801
Population, 2020 census P1190,934660,7411,097,379
Median age B0100232.838.040.6
Under 18 B0100120.1%20.1%18.8%
65 and over B0100111.6%16.3%18.7%
Households B1100171,497259,210441,570
Foreign born B0500233.5%20.9%15.3%
Median household income B19013$68,119$78,787$87,796
Median family income B19113$80,994$99,120$112,375
Per capita income B19301$37,138$41,523$47,150
Poverty rate B1700120.7%13.4%11.2%
Unemployment rate B230258.2%6.6%5.8%
Civilian labor force B23025101,717358,122594,253
Mean commute (minutes) B0801325.025.925.5
Bachelor's degree or higher B1500334.6%32.3%37.7%
Housing units B2500179,423277,740485,932
Owner-occupied B2500341.4%56.9%63.6%
Renters B2500358.6%43.1%36.4%
Median home value B25077$362,200$373,600$404,200
Median gross rent B25064$1,408$1,312$1,342
White, not Hispanic B0300233.1%56.5%68.0%
Black B0300210.2%7.0%4.9%
Hispanic or Latino B0300245.3%25.6%17.7%
Asian B030026.2%4.2%3.5%
American Indian and Alaska Native B030020.3%0.2%0.1%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Providence, RI.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.